This SDS packet was issued with item:

078904881

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

070437244 070437384 070437392 070437400 070437418 073662509 078008630 078434772 078688799 078889382 078904583 078904584 078923730 078944136

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078412824



Revision date: 11-Nov-2016

Version: 1.1

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.)

Trade Name: Synonyms: Chemical Family: Bupivacaine Injection Bupivacaine Spinal (Bupivacine in Dextrose, USP) Not determined

Pfizer Ltd

CT13 9NJ

Ramsgate Road

Sandwich, Kent

United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as anesthetic agent

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4

Label Elements

Signal Word: Hazard Statements:	Warning H302 - Harmful if swallowed		
Precautionary Statements:	P264 - Wash hands thoroughly after handling P270 - Do not eat, drink or smoke when using this product P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell		
	P330 - Rinse mouth P501 - Dispose of contents/container in accordance with all local and national regulations		

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016 Page 2 of 10

Version: 1.1



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU	GHS Classification	%
_		EINECS/ELINCS		
		List		
Bupivacaine Hydrochloride	14252-80-3	Not Listed	Acute Tox. 2 (H300)	= 0.75</td
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314)	**
			STOT SE 3 (H335)	
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		
Methylparaben	99-76-3	202-785-7	Not Listed	*
Dextrose	14431-43-7	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures Eve Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention
_,	immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

Most Important Symptoms and Effe Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	conditions Identification and/or Section 11 - Toxicological Information.			
Indication of the Immediate Medical Notes to Physician:	Attention and Special Treatment Needed None			
5. FIRE FIGHTING MEASURE	S			
Extinguishing Media:	Extinguish fires with CO2, extinguishing powder, foam, or water.			
Special Hazards Arising from the So Hazardous Combustion Products:	ubstance or Mixture Formation of toxic gases is possible during heating or fire.			
Fire / Explosion Hazards:	Not flammable.			
Advice for Fire-Fighters During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.				
6. ACCIDENTAL RELEASE MEASURES				
•	quipment and Emergency Procedures should wear appropriate personal protective equipment (see Section 8). Minimize exposure.			
Environmental Precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.				
Methods and Material for Containm	Methods and Material for Containment and Cleaning Up			

absorbent material and transfer to labeled container for disposal.

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Contain the source of the spill or leak if it is safe to do so. Collect spill with a non-combustible

PZ03230

Specific end use(s): Pharmaceutical drug product

collectors, HEPA filtration systems or other equivalent controls.

area thoroughly.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Measures for Cleaning /

7. HANDLING AND STORAGE

Precautions for Safe Handling

Additional Consideration for

Collecting:

Large Spills:

Refer to available public information for specific member state Occupational Exposure Limits.

Page 3 of 10

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

8. EXPOSURE CONTROLS / PERSONAL PROTECTION		
Bupivacaine Hydrochloride		
Pfizer OEL TWA-8 Hr:	20 µg/m³	
HYDROCHLORIC ACID	-	
ACGIH Ceiling Threshold Limit:	2 ppm	
Australia PEAK	5 ppm 7.5 mg/m³	
Austria OEL - MAKs	5 ppm	
	8 mg/m ³	
Belgium OEL - TWA	5 ppm	
-	8 mg/m ³	
Bulgaria OEL - TWA	5 ppm	
	8.0 mg/m ³	
Cyprus OEL - TWA	5 ppm 8 mg/m ³	
Czech Republic OEL - TWA	8 mg/m ³	
Estonia OEL - TWA	5 ppm	
	8 mg/m ³	
Germany - TRGS 900 - TWAs	2 ppm	
	3 mg/m ³	
Germany (DFG) - MAK	2 ppm	
Greece OEL - TWA	3.0 mg/m ³ 5 ppm	
Greece OEL - TWA	5 ppm 7 mg/m ³	
Hungary OEL - TWA	8 mg/m ³	
Ireland OEL - TWAs	5 ppm	
	8 mg/m ³	
Italy OEL - TWA	5 ppm	
	8 mg/m ³	
Japan - OELs - Ceilings	2 ppm 3.0 mg/m ³	
Latvia OEL - TWA	5 ppm	
	8 mg/m ³	
Lithuania OEL - TWA	5 ppm	
	8 mg/m ³	
Luxembourg OEL - TWA	5 ppm	
Malta OEL - TWA	8 mg/m ³ 5 ppm	
	8 mg/m ³	
Netherlands OEL - TWA	8 mg/m ³	
Poland OEL - TWA	5 mg/m ³	
Portugal OEL - TWA	5 ppm	
	8 mg/m ³	
Romania OEL - TWA	5 ppm	
Slovakia OEL - TWA	8 mg/m ³ 5 ppm	
SIOVANIA ULL - I WA	8.0 mg/m ³	
Slovenia OEL - TWA	5 ppm	
	8 mg/m ³	
Spain OEL - TWA	5 ppm	
	7.6 mg/m ³	

Page 4 of 10

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

	PERSONAL PROTECTION	
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³	
Vietnam OEL - TWAs	5 mg/m ³	
	3 mg/m	
DIUM HYDROXIDE		
ACGIH Ceiling Threshold Lir	nit: 2 mg/m ³	
Australia PEAK	2 mg/m ³	
Austria OEL - MAKs	2 mg/m ³	
Bulgaria OEL - TWA	2.0 mg/m ³	
Czech Republic OEL - TWA	1 mg/m ³	
Estonia OEL - TWA	1 mg/m ³	
France OEL - TWA	2 mg/m ³	
Greece OEL - TWA	2 mg/m ³	
Hungary OEL - TWA	2 mg/m ³	
Japan - OELs - Ceilings	2 mg/m ³	
Latvia OEL - TWA	0.5 mg/m ³	
OSHA - Final PELS - TWAs:	2 mg/m^3	
Poland OEL - TWA	0.5 mg/m ³	
Slovakia OEL - TWA	2 mg/m ³	
Slovenia OEL - TWA	2 mg/m ³	
Sweden OEL - TWAs	1 mg/m ³	
Switzerland OEL -TWAs	2 mg/m^3	
	J J	
osure Controls		
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General	
	room ventilation is adequate unless the process generates dust, mist or fumes. Keep airbo	
	contamination levels below the exposure limits listed above in this section.	
Personal Protective	Refer to applicable national standards and regulations in the selection and use of personal	
Equipment:	protective equipment (PPE). Contact your safety and health professional or safety equipme	
	supplier for assistance in selecting the correct protective clothing/equipment based on an	
	assessment of the workplace conditions, other chemicals used or present in the workplace specific operational processes.	
	specific operational processes.	
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is	
Handol	possible and for bulk processing operations. (Protective gloves must meet the standards in	
	accordance with EN374, ASTM F1001 or international equivalent.)	
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the	
	standards in accordance with EN166, ANSI Z87.1 or international equivalent.)	
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible	
	for bulk processing operations. (Protective clothing must meet the standards in accordance	
	with EN13982, ANSI 103 or international equivalent.)	
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is	
	exceeded, wear an appropriate respirator with a protection factor sufficient to control exposi-	
	to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must	
	meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international	
	equivalent.)	

Page 5 of 10

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016 Page 6 of 10

Version: 1.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Odor: Molecular Formula:	Solution No data available. Mixture		Color: Odor Threshold: Molecular Weight:	Clear, colorless No data available. Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, E Water for injection No data available Sodium chloride No data available Bupivacaine Hydrochloride No data available Dextrose No data available HYDROCHLORIC ACID No data available SODIUM HYDROXIDE No data available Methylparaben No data available	No data available No data available No data available. No data available. Indpoint, Value)			
Decomposition Temperature (°C): Evaporation Rate (Gram/s): Vapor Pressure (kPa): Vapor Density (g/ml): Relative Density: Viscosity:	No data available No data available No data available No data available No data available No data available			
Flammablity: Autoignition Temperature (So Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liqui Lower Explosive Limits (Liqui	d) (% by Vol.):	No data ava No data ava No data ava No data ava No data ava	ilable ilable ilable	

10. STABILITY AND REACTIVITY

No data available tability: Stable under normal conditions of use. of Hazardous Reactions
of Hazardous Reactionsizing Properties:No data availablelitions to Avoid:Fine particles (such as dust and mists) may fuel fires/explosions.npatible Materials:As a precautionary measure, keep away from strong oxidizersrdous DecompositionNo data available
rdous Decomposition No data available ucts:

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects	
General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	May cause mild eye irritation. May cause slight skin irritation. (based on components) . Anesthetic drug: may cause central nervous system and cardiovascular system effects
Known Clinical Effects:	Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Bupivacaine Hydrochloride

RabbitOralLD5018 mg/kgRatPara-periostealLD506mg/kgRatSubcutaneousLD5043mg/kgMouseIntravenousLD506.1mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Bupivacaine Hydrochloride Prenatal & Postnatal Development Intravenous 0.6 mg/kg LOAEL Neonatal toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID Bacterial Mutagenicity (Ames) In Vivo Micronucleus Rat	Salmonella Negative egative	
Carcinogen Status:	None of the components of this formulation	are listed as a carcinogen by IARC, NTP or OSHA.
HYDROCHLORIC ACID IARC:	Group 3 (Not Classifiable)	

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016 Page 8 of 10

Version: 1.1

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Bupivacaine Hydrochloride
CERCLA/SARA 313 Emission reporting
California Proposition 65
EU EINECS/ELINCS List

Not Listed Not Listed Not Listed

Methylparaben CERCLA/SARA 313 Emission reporting

Not Listed

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

15. REGULATORY INFORMATION	
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7
HYDROCHLORIC ACID	
CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	5000 lb
and their Reportable Quantities:	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	231-595-7
SODIUM HYDROXIDE	
CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances	1000 lb
and their Reportable Quantities:	454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	215-185-5
Dextrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources:	Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Revision date:	11-Nov-2016

Material Name: Bupivacaine Hydrochloride Injection (Hospira, Inc.) Revision date: 11-Nov-2016

Prepared by:

Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

PZ03230

Page 10 of 10